ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Gilead Sciences to Promote Low-Cost HIV Medicine in Developing World

By Chelsea Stevenson Gilead Sciences Inc. (GILD) said it plans to partner with Mylan Inc. (MYL), Ranbaxy Laboratories Ltd. (500359.BY) and Strides Arcolab Ltd. (532531.BY) to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries. The medicine includes single tablet regimens and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Under the new agreement, Gilead will provide a technology transfer for the manufacture of emtricitabine as well as funding to reduce overall manufacturing costs. Emtricitabine is marked by Gilead under the name Emtriva and the fixed-dose is available under the name Truvada. But costs are an obstacle for high-volume production. More than 2.7 million patients living with HIV in developing countries are currently receiving a medicine innovated by Gilead and subsequently licensed to Indian generic partners, as part of the company's efforts to increase global access. Strides Arcolab Managing Director Arun Kumar said the partnership will also re-enforce commitments to provide affordable drugs in the tuberculosis and malaria fields. Gilead's second-quarter earnings slid last week as the company posted a double-digit increase in costs, which offset its strong revenue growth. Earlier this year, the company bought Pharmasset Inc. for more than $11 billion, expecting the company to help accelerate the development of treatments for hepatitis C. Write to Chelsea Stevenson at Subscribe to WSJ:

Stock News for Abbott Labs (ABT)
10/24/201617:05:03Current Report Filing (8-k)
10/20/201611:17:00People's Republic of China Clears Abbott Acquisition of Alere
10/20/201603:03:00Business Watch -- WSJ
10/19/201614:52:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake...
10/19/201612:18:00St. Jude Medical's Sales Rise 12% -- Update
10/19/201610:23:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake--Update
10/19/201610:10:00St. Jude Medical's Sales Rise 12%
10/19/201609:53:00St. Jude Medical's Sales Rise 12%
10/19/201609:50:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19/201609:43:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19/201607:53:35Current Report Filing (8-k)
10/19/201607:45:00Abbott Reports Third-Quarter 2016 Results
10/18/201609:20:00Abbott, St. Jude Medical to Sell $1.1 Billion in Assets
10/18/201608:00:00St. Jude Medical and Abbott to Sell Portion of Vascular Closure...
10/18/201608:00:00St. Jude Medical and Abbott to Sell Portion of Vascular Closure...
10/17/201622:10:00St. Jude Medical Forms Cybersecurity Advisory Group
10/17/201621:20:00St. Jude Medical Forms Cybersecurity Advisory Group
10/14/201611:15:00The Innovation of Wearable Technology and Medical Devices
10/13/201620:40:00INVESTOR ALERT: Khang & Khang LLP Announces an Investigation...
10/13/201618:40:00SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations